Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00388154 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer
A Phase 2 study of Endometrial Cancer, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 3
- Study locations
NCT00388154: Completed Phase 2 study of Endometrial Cancer, sponsored by M.D. Anderson Cancer Center.
NCT00388154 is a Phase 2 study of Endometrial Cancer that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 21 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00388154, a Phase 2 study of Endometrial Cancer, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 3
- Study locations
Study Summary
Primary Objective: * To estimate the antitumor activity of the combination of gemcitabine and cisplatin in patients with advanced (stage III or IV) or recurrent endometrial cancer. Secondary Objective: * To determine the nature and degree of toxicity of the combination of gemcitabine and cisplatin in this cohort of patients.
Primary Outcome
Response Evaluation Criteria In Solid Tumors (RECIST): Complete Response (CR): disappearance all target \& nontarget lesions, absence new lesions, documented by 2 disease assessments 4 weeks apart; Partial response (PR): 30% decrease in sum longest diameter (LD) all measurable target lesions (baseline sum LDs as reference) \& absence of progression of nontarget lesions or development of new, documented by 2 disease assessments 4 weeks apart. When only target lesion solitary pelvic mass measurabl
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Gemcitabine
Study Locations (3)
Texas
- St. Lukes Episcopal Hospital - Houston
- UT MD Anderson Cancer Center - Houston
- The Woman's Hospital of Texas - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2004-08 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
What the finished NCT00388154 record still lists
NCT00388154 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cisplatin is the first listed.
NCT00388154 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00388154 about?
NCT00388154 is a clinical study titled "Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer". Primary Objective: * To estimate the antitumor activity of the combination of gemcitabine and cisplatin in patients with advanced (stage III or IV) or recurrent endometrial cancer. Secondary Objective: * To determine the nature and degree of toxicity of the combination of gemcitabine and cisplati...
What is the current status of trial NCT00388154?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2004-08. Estimated completion is 2013-11.
What conditions does trial NCT00388154 study?
This clinical trial studies the following conditions: Endometrial Cancer.
What interventions are being tested in trial NCT00388154?
The interventions under investigation include: Cisplatin (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00388154?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00388154 being conducted?
This trial has 3 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00388154's enrollment target sits among peer trials
21 166th of 181 higher than 12 of 181 other Endometrial Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
RECRUITING · Phase 2
-
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
RECRUITING · Phase 2
-
Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery
RECRUITING · Phase 2
-
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
RECRUITING · Phase 2
-
Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia